<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04740164</url>
  </required_header>
  <id_info>
    <org_study_id>2020-1014</org_study_id>
    <secondary_id>NCI-2021-00118</secondary_id>
    <secondary_id>2020-1014</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT04740164</nct_id>
  </id_info>
  <brief_title>A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP</brief_title>
  <official_title>A Randomized Study to Compare LMA® Gastro™, a Dual Channel Supraglottic Airway (SGA) Device, to Oxygenation With Standard Nasal Cannula for Endoscopic Retrograde Cholangiopancreatography (ERCP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial compares the effect of LMA Gastro, a dual channel supraglottic airway&#xD;
      (SGA) device, to oxygenation with standard nasal cannula for endoscopic retrograde&#xD;
      cholangiopancreatography (ERCP). An ERCP is a combination of imaging scans and endoscopy that&#xD;
      helps doctors diagnose and treat conditions of the pancreas and bile ducts that requires&#xD;
      general anesthesia or procedural sedation. Anesthesiologists often use SGAs or nasal cannulas&#xD;
      to help patients breathe while they are asleep during procedures. An SGA consists of an&#xD;
      airway tube that connects to a mask, which is inserted through the mouth and placed at the&#xD;
      back of the throat to keep the airway open while patients are under anesthesia or sedation.&#xD;
      The nasal cannula is a device that fits in a patient's nostrils and delivers oxygen through a&#xD;
      small, flexible tube while they are under anesthesia or sedation. The goal of this trial is&#xD;
      to compare the effects of the LMA Gastro to nasal cannula when used to deliver oxygen to&#xD;
      patients while they are asleep during their ERCP procedure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To compare the incidence of desaturation (oxygen saturation [SpO2] &lt; 90%) between patients&#xD;
      undergoing ERCP with LMA Gastro versus (vs) standard nasal cannula.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the incidence of additional airway maneuvers (jaw thrust/chin lift/placement&#xD;
      of oral airway or/nasal trumpet/intubation).&#xD;
&#xD;
      II. To evaluate the incidence of withdrawal of duodenoscope from the airway to facilitate&#xD;
      airway support.&#xD;
&#xD;
      III. To evaluate the incidence of adverse events. IV. To evaluate times related to anesthesia&#xD;
      and procedure (defined as &quot;anesthesia start to anesthesia end&quot; and &quot;procedure start to&#xD;
      procedure end&quot; respectively).&#xD;
&#xD;
      V. To evaluate time from procedure end to anesthesia end. VI. To describe hemodynamics within&#xD;
      the two groups (recorded blood pressures, heart rates, oxygen saturations, and end tidal&#xD;
      carbon dioxide [CO2]).&#xD;
&#xD;
      VII. To evaluate anesthesiologist placing the device (training video viewed, number of&#xD;
      practice attempts, years of experience).&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients undergo ERCP with LMA Gastro.&#xD;
&#xD;
      ARM II: Patients undergo ERCP with standard nasal cannula.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of desaturations (oxygen saturation [SpO2] &lt; 90%)</measure>
    <time_frame>Up to completion of endoscopic retrograde cholangiopancreatography</time_frame>
    <description>Defined as at any time under sedation during procedure a patient has experienced at least one episode of desaturations. Fisher's exact test will be used to compare the percentage of patients with desaturations (SpO2 &lt; 90%) between LMA Gastro and standard nasal cannula groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of additional airway maneuvers</measure>
    <time_frame>Up to completion of endoscopic retrograde cholangiopancreatography</time_frame>
    <description>Will be summarized through frequencies and percentages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to completion of endoscopic retrograde cholangiopancreatography</time_frame>
    <description>Will be summarized through frequencies and percentages.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of withdrawal of duodenoscope from airway to facilitate airway support</measure>
    <time_frame>Up to completion of endoscopic retrograde cholangiopancreatography</time_frame>
    <description>Will be summarized through frequencies and percentages.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Bile Duct Carcinoma</condition>
  <condition>Gallbladder Carcinoma</condition>
  <condition>Pancreatic Ductal Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm I (ERCP with LMA Gastro)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo ERCP with LMA Gastro.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (ERCP with standard nasal cannula)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo ERCP with standard nasal cannula.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic Retrograde Cholangiopancreatography</intervention_name>
    <description>Undergo ERCP with LMA Gastro</description>
    <arm_group_label>Arm I (ERCP with LMA Gastro)</arm_group_label>
    <other_name>ERCP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic Retrograde Cholangiopancreatography</intervention_name>
    <description>Undergo ERCP with standard nasal cannula</description>
    <arm_group_label>Arm II (ERCP with standard nasal cannula)</arm_group_label>
    <other_name>ERCP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (&gt;= 18 years old) undergoing ERCP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with propofol allergy&#xD;
&#xD;
          -  Patients at increased aspiration risk&#xD;
&#xD;
          -  Patients with abnormal head/neck pathology preventing LMA Gastro placement&#xD;
&#xD;
          -  Patients with surgical or radiation treatment to the head/neck making LMA Gastro&#xD;
             placement difficult&#xD;
&#xD;
          -  Patient with known difficult airway requiring advanced intubation equipment (with the&#xD;
             exception of the video-laryngoscope) in the past&#xD;
&#xD;
          -  Esophagectomy patients&#xD;
&#xD;
          -  Patients already intubated upon arrival to endoscopy suite&#xD;
&#xD;
          -  Patients undergoing endoscopic ultrasound (EUS)&#xD;
&#xD;
          -  Patients with body mass index (BMI) &gt;= 35 kg/m^2&#xD;
&#xD;
          -  Patients with hypoxemia (SpO2 &lt; 94% on room air or on home oxygen)&#xD;
&#xD;
          -  American Society of Anesthesiology (ASA) Physical Status IV-V&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Hagan</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Hagan</last_name>
      <phone>713-563-0034</phone>
    </contact>
    <investigator>
      <last_name>Katherine Hagan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 29, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

